BioLife Solutions, Inc. (BLFS): Price and Financial Metrics
BLFS Price/Volume Stats
Current price | $17.20 | 52-week high | $24.50 |
Prev. close | $17.00 | 52-week low | $8.92 |
Day low | $16.74 | Volume | 10,719 |
Day high | $17.20 | Avg. volume | 420,296 |
50-day MA | $17.49 | Dividend yield | N/A |
200-day MA | $16.00 | Market Cap | 779.16M |
BLFS Stock Price Chart Interactive Chart >
BLFS POWR Grades
- BLFS scores best on the Growth dimension, with a Growth rank ahead of 51.7% of US stocks.
- BLFS's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
- BLFS's current lowest rank is in the Quality metric (where it is better than 1.03% of US stocks).
BLFS Stock Summary
- BLFS's went public 31.63 years ago, making it older than 80.69% of listed US stocks we're tracking.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.24 for BIOLIFE SOLUTIONS INC; that's greater than it is for only 14.87% of US stocks.
- The volatility of BIOLIFE SOLUTIONS INC's share price is greater than that of 82.37% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to BLFS, based on their financial statements, market capitalization, and price volatility, are PHUN, APPS, ADN, EHTH, and SKLZ.
- BLFS's SEC filings can be seen here. And to visit BIOLIFE SOLUTIONS INC's official web site, go to www.biolifesolutions.com.
BLFS Valuation Summary
- BLFS's price/sales ratio is 4.6; this is 109.09% higher than that of the median Healthcare stock.
- BLFS's price/sales ratio has moved up 3.4 over the prior 243 months.
Below are key valuation metrics over time for BLFS.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
BLFS | 2023-12-29 | 4.6 | 2.2 | -6.9 | -7.3 |
BLFS | 2023-12-28 | 4.8 | 2.2 | -7.1 | -7.5 |
BLFS | 2023-12-27 | 4.8 | 2.2 | -7.2 | -7.6 |
BLFS | 2023-12-26 | 4.7 | 2.2 | -7.1 | -7.5 |
BLFS | 2023-12-22 | 4.6 | 2.1 | -6.8 | -7.2 |
BLFS | 2023-12-21 | 4.5 | 2.1 | -6.7 | -7.1 |
BLFS Growth Metrics
- Its 2 year revenue growth rate is now at 310.3%.
- Its 4 year net cashflow from operations growth rate is now at 125.97%.
- The 4 year net income to common stockholders growth rate now stands at 349.74%.
The table below shows BLFS's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 154.805 | -17.119 | -103.833 |
2022-06-30 | 147.858 | -16.532 | -93.799 |
2022-03-31 | 138.529 | -14.337 | -13.584 |
2021-12-31 | 119.156 | -4.593 | -7.635 |
2021-09-30 | 96.577 | -1.562 | 4.748 |
2021-06-30 | 74.056 | -4.147 | 3.538 |
BLFS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BLFS has a Quality Grade of D, ranking ahead of 17.91% of graded US stocks.
- BLFS's asset turnover comes in at 0.249 -- ranking 137th of 186 Medical Equipment stocks.
- MASI, NVNO, and ZYXI are the stocks whose asset turnover ratios are most correlated with BLFS.
The table below shows BLFS's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.249 | 0.491 | -0.211 |
2021-03-31 | 0.269 | 0.552 | -0.611 |
2020-12-31 | 0.301 | 0.571 | -0.032 |
2020-09-30 | 0.335 | 0.593 | -0.621 |
2020-06-30 | 0.383 | 0.615 | -0.137 |
2020-03-31 | 0.417 | 0.654 | 0.904 |
BLFS Price Target
For more insight on analysts targets of BLFS, see our BLFS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $62.14 | Average Broker Recommendation | 1.56 (Moderate Buy) |
BioLife Solutions, Inc. (BLFS) Company Bio
BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company was founded in 1987 and is based in Bothell, Washington.
Latest BLFS News From Around the Web
Below are the latest news stories about BIOLIFE SOLUTIONS INC that investors may wish to consider to help them evaluate BLFS as an investment opportunity.
Analysts Just Shaved Their BioLife Solutions, Inc. (NASDAQ:BLFS) Forecasts DramaticallyThe analysts covering BioLife Solutions, Inc. ( NASDAQ:BLFS ) delivered a dose of negativity to shareholders today, by... |
BioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales CyclesConestoga Capital Advisors, an asset management company, released its “Micro Cap Strategy” third-quarter 2023 investor letter. A copy of the same can be downloaded here. The micro capitalization segment of the market proved the most challenging in the quarter with the Russell Micro Cap Index declining -7.93%. The Russell Micro Cap Growth Index fell further with a […] |
BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call TranscriptBioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call Transcript November 9, 2023 BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.38. Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and Analyst Conference Call. At this time, all participants […] |
BioLife Solutions Reports Third Quarter 2023 Financial ResultsBioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene therapy (CGT) and broader biopharma markets, today announced financial results for the third quarter and nine months of 2023. |
BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter financial results will be released after market close on Thursday, November 9, 2023. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company's financial results and a general business upda |
BLFS Price Returns
1-mo | -2.55% |
3-mo | 12.64% |
6-mo | 35.65% |
1-year | -17.15% |
3-year | -55.62% |
5-year | -19.10% |
YTD | 5.85% |
2023 | -10.71% |
2022 | -51.17% |
2021 | -6.57% |
2020 | 146.54% |
2019 | 34.50% |
Continue Researching BLFS
Want to do more research on Biolife Solutions Inc's stock and its price? Try the links below:Biolife Solutions Inc (BLFS) Stock Price | Nasdaq
Biolife Solutions Inc (BLFS) Stock Quote, History and News - Yahoo Finance
Biolife Solutions Inc (BLFS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...